Molecular Formula | C21H22Cl2N4O2 |
Molar Mass | 433.33098 |
Density | 1.359 |
Boling Point | 682.8±55.0 °C(Predicted) |
Solubility | DMSO: ≥ 45 mg/mL |
pKa | 13.34±0.50(Predicted) |
Storage Condition | -20℃ |
In vitro study | In a A375 melanoma cell containing the b-RAFV600E mutant, Ulixertinib reduced the level of phosphorylated ERK2 (pERK) and the level of phosphorylation of the downstream kinase RSK (pRSK) with an IC50 of 4.1/0.14 μm, respectively. Ulixertinib also inhibited A375 cell proliferation with an IC50 of 180 nM. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.308 ml | 11.539 ml | 23.077 ml |
5 mM | 0.462 ml | 2.308 ml | 4.615 ml |
10 mM | 0.231 ml | 1.154 ml | 2.308 ml |
5 mM | 0.046 ml | 0.231 ml | 0.462 ml |